☆ 4.7 Article

Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population

VACCINES (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

Vivek Naranbhai et al.

Summary: The study investigated the immune responses to SARS-CoV-2 vaccines in cancer patients, showing that the vaccine-induced immune responses were quantitatively lower in cancer patients compared to healthy controls, recommending antibody testing to identify those who may benefit from additional vaccine doses.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Infectious Diseases

Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay

Hideaki Kato et al.

Summary: The researchers analyzed samples from Japanese healthcare workers who had received two doses of the BNT162b2 vaccine and found that SP IgG titers were positively correlated with NT50 titers at 4 and 6 weeks after the first dose. They also observed weaker immune responses against the Beta and Delta variants compared to the original strain.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2022)

Add to Collection

Article Virology

Induction of humoral and cellular immune responses to COVID-19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers

Maria Nikolova et al.

Summary: Installing efficient protective immunity by anti-SARS-CoV-2 vaccines is the only current means to overcome coronavirus disease 2019 pandemics. The study showed that both mRNA and vector vaccines induced potent and comparable humoral and cellular immune responses against SARS-CoV-2. The number of vaccine doses and age of the participants had an impact on the level and longevity of protection provided by the vaccines.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Editorial Material Infectious Diseases

Protective immunity after recovery from SARS-CoV-2 infection

Noah Kojima et al.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

Kang Wang et al.

Summary: The Omicron variant of SARS-CoV-2 is highly resistant to neutralizing antibodies, which raises concerns about the effectiveness of antibody therapies and vaccines. A study found that individuals who received two or three doses of an inactivated SARS-CoV-2 vaccine had varying rates of seroconversion for neutralizing antibodies. The effectiveness of neutralizing antibodies against Omicron was significantly lower in individuals who received three vaccine doses. However, monoclonal antibodies derived from individuals who received three vaccine doses showed strong neutralizing activity against all variants of concern, including Omicron.

NATURE (2022)

Add to Collection

Article Respiratory System

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong

Chris Ka Pun Mok et al.

Summary: The study found that vaccination with BNT162b2 induces significantly stronger humoral immune responses than CoronaVac. Additionally, BNT162b2 vaccine recipients had higher levels of antibody protection threshold. Age was negatively correlated with antibody levels post-vaccination. Both vaccines induced SARS-CoV-2-specific T-cell responses, but CoronaVac elicited higher levels of structural protein-specific T-cell responses.

RESPIROLOGY (2022)

Add to Collection

Letter Immunology

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year

Zheng Zhang et al.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

Article Immunology

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant

Xiaoling Yu et al.

Summary: This study investigated recipients who were immunized with three doses of a COVID-19-inactivated vaccine, and found that the vaccine effectively generated potent neutralizing activity against the Omicron variant.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

Article Immunology

Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study

Paskorn Sritipsukho et al.

Summary: During the period when the delta variant was dominant, the two-dose CoronaVac plus one BNT162b2 or ChAdOx1 nCoV-19 booster regimens were highly effective in preventing COVID-19.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

Article Immunology

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

Timothy A. Bates et al.

Summary: This study found that individuals who previously recovered from COVID-19 and received vaccination (hybrid immunity) have enhanced immune responses. The effects of post-vaccination breakthrough infections on humoral immune response needs further investigation. However, regardless of whether it occurs before or after vaccination, natural infection substantially boosts the quantity, quality, and breadth of humoral immune response.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Article Infectious Diseases

Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals

Nuria Tormo et al.

Summary: In this study, we analyzed the immunological response during vaccination and found that individuals previously infected by SARS-CoV-2 showed significant immune response after the first vaccine dose, while those who were not infected showed lower response after each dose. Older individuals who were infected responded better to the vaccine, while younger uninfected individuals had the best response. Therefore, the second vaccine dose may not be necessary for individuals with previous COVID-19 infection, and QuantiFERON (R) can be a useful method for monitoring SARS-CoV-2 cellular immunity.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2022)

Add to Collection

Article Cell Biology

Circulating B10 regulatory cells are decreased in severe and critical COVID-19

Rodrigo Cervantes-Diaz et al.

Summary: During COVID-19 onset, there is a significant reduction in the frequency of B10 subset, which is correlated with disease severity. This suggests an aberrant role of B10 cells in immune responses against SARS-CoV-2.

JOURNAL OF LEUKOCYTE BIOLOGY (2022)

Add to Collection

Editorial Material Respiratory System

COVID-19 vaccine-induced immunity: Head-to-head comparison of mRNA (BNT162b2) versus inactivated (CoronaVac) vaccines

Benjamin Kagina et al.

RESPIROLOGY (2022)

Add to Collection

Review Virology

mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People

Anna Rosa Garbuglia et al.

Summary: This review provides an overview of the global impact of SARS-CoV-2 and the development of COVID-19 vaccines. It also discusses the immune response elicited by mRNA and adenovirus-based vaccines in the general population. Furthermore, it explores the use and efficacy of these vaccines in people living with HIV, highlighting several open questions.

VIRUSES-BASEL (2022)

Add to Collection

Article Immunology

Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation

Maria G. Byazrova et al.

Summary: The development of effective vaccines against SARS-CoV-2 is crucial. The study found that Sputnik V vaccination can result in robust B cell immunity, which is influenced by the individuals' history of SARS-CoV-2 infection. The research shows that B memory cell responses to Sputnik V play a significant role in neutralizing the virus and may provide insights into future responses against emerging variants.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka

Chandima Jeewandara et al.

Summary: In order to determine the immune response to different vaccines against SARS-CoV-2, researchers compared antibody responses in individuals who had received different vaccines in Sri Lanka. The results showed that the Moderna vaccine elicited the highest levels of ACE2 blocking antibodies, while the Sinopharm vaccine had the lowest levels. Further studies are needed to understand the impact on clinical outcomes.

IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

3Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum

Amit Kaura et al.

Summary: This study compared the effectiveness of single-dose strategies for Oxford-AstraZeneca and Pfizer-BioNTech vaccines in different age groups against SARS-CoV-2 infection, finding that single-dose vaccination was effective at reducing COVID-19 mortality and hospitalization rates, especially in older adults.

ECLINICALMEDICINE (2022)

Add to Collection

Article Immunology

Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers

Eric D. Laing et al.

Summary: Antibodies against SARS-CoV-2 decrease but remain detectable for 6 months postvaccination. The duration of neutralizing titers is shorter against Delta variant compared to the wild-type virus. Out of 227 vaccinated healthcare workers, only 2 experienced mild breakthrough infections, despite 59 individuals showing serologic evidence of SARS-CoV-2 infection.

EMERGING INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia

Naranjargal J. Dashdorj et al.

Summary: The study found marked differences in antibody responses among individuals in Mongolia vaccinated with different COVID-19 vaccines, with lower levels of antibodies stimulated by the Sinopharm and Sputnik V vaccines. Those who recover from infection after vaccination typically achieve high antibody titers.

CELL HOST & MICROBE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naive and previously infected individuals

Duaa W. Al-Sadeq et al.

Summary: The study found that individuals with prior infection produced higher levels of antibodies compared to those who were vaccine-naive, especially for individuals vaccinated with BNT162b2.

JOURNAL OF TRAVEL MEDICINE (2021)

Add to Collection

Review Virology

Toward an understanding of regulatory T cells in COVID-19: A systematic review

Mahsa Rahimzadeh et al.

Summary: The study found a trend towards decreasing levels of Treg cells in severe COVID-19 patients, suggesting a potential role of Tregs in the pathogenesis of COVID-19. Further research on the functional aspects of Tregs is necessary to illustrate their potential role in COVID-19 disease.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Chemistry, Multidisciplinary

The dawn of mRNA vaccines: The COVID-19 case

Rein Verbeke et al.

Summary: In less than a year since the COVID-19 pandemic outbreak, mRNA vaccines have made significant progress, with two receiving emergency use authorization and one moving to phase 3 clinical testing. These mRNA vaccines represent a new class of vaccine products, encoding the SARS-CoV-2 Spike glycoprotein to deliver mRNA to cells. The review provides a detailed overview of the composition, clinical performance, and design considerations of the most advanced mRNA vaccines, highlighting new insights and areas for future research and optimization.

JOURNAL OF CONTROLLED RELEASE (2021)

Add to Collection

Article Geriatrics & Gerontology

Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

Istvan Valyi-Nagy et al.

Summary: This study compared the humoral and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines against the SARS-CoV-2 virus, revealing significant quantitative and qualitative differences between the two. BBIBP-CorV vaccine induced high levels of antibody responses in healthy individuals, while BNT162b2 showed slightly higher T cell responses.

GEROSCIENCE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Previous COVID-19 Infection and Antibody Levels After Vaccination

Hamad Ali et al.

Summary: Individuals with previous COVID-19 infection showed higher and more sustained levels of SARS-CoV-2 antibodies after COVID-19 vaccination compared to those without previous infection. Vaccinated individuals without previous COVID-19 infection experienced a faster decline in IgG and neutralizing antibodies compared to those with prior infection. Efforts should be made to prioritize vaccination for more individuals, especially those without previous COVID-19 infection, due to inconsistent vaccine supply globally.

FRONTIERS IN PUBLIC HEALTH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Review Microbiology

Antibody and B cell responses to SARS-CoV-2 infection and vaccination

Katharina Roltgen et al.

Summary: Human immune responses to SARS-CoV-2 have made significant progress in understanding the nature of antibody responses and their role in protecting against infection or modulating the severity of COVID-19, aiding in the development of effective vaccines. However, important questions remain unanswered regarding the duration and effectiveness of antibody responses, immunity differences between infection and vaccination, cellular basis for serological findings, and the potential impact of viral variants on current immunity.

CELL HOST & MICROBE (2021)

Add to Collection

Article Infectious Diseases

Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan

Takahiro Kageyama et al.

Summary: The study aimed to determine antibody responses in healthcare workers following the BNT162b2 mRNA COVID-19 vaccine and identified factors that predict the response. Results showed that healthcare workers have good antibody responses to the vaccine, with factors like immunosuppressive medication, age, and time from vaccination affecting antibody titers.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Letter Medicine, General & Internal

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Deborah Steensels et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Jackson S. Turner et al.

Summary: The study found that individuals who had recovered from mild SARS-CoV-2 infections showed rapid decline of serum anti-SARS-CoV-2 spike protein antibodies in the first 4 months after infection, followed by a more gradual decrease over the following 7 months but remaining detectable at least 11 months after infection. This suggests that mild infection with SARS-CoV-2 can induce robust antigen-specific, long-lived humoral immune memory in humans.

NATURE (2021)

Add to Collection

Letter Medicine, General & Internal

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Dan H. Barouch et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Immunology

The need for broadly protective COVID-19 vaccines: Beyond S-only approaches

Gregory A. Poland et al.

VACCINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021

Heather M. Scobie et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Review Immunology

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

Franz X. Heinz et al.

Summary: COVID-19 vaccines have been rapidly developed using different technologies, including mRNA, adenoviral vectors, and inactivated vaccines. They all rely on the viral spike protein of SARS-CoV-2 to induce neutralizing antibodies, but the presentation of this key antigen to the immune system varies between different vaccine categories.

NPJ VACCINES (2021)

Add to Collection

Review Immunology

Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3

Yu-Jing Fan et al.

Summary: This systematic review and meta-analysis compared the safety and efficacy of COVID-19 vaccines, finding that mRNA vaccines were more associated with serious adverse events, while two doses of mRNA vaccines were most effective in reducing the risk of SARS-COV-2 infection. All vaccines were effective in reducing the risk of severe infection.

VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine

Yu Min Kang et al.

Summary: The study found that both ChAdOx1 and BNT162b2 vaccines induced antibody responses, with higher levels observed in the BNT162b2 group. In the ChAdOx1 vaccine group, women had higher levels of neutralizing antibodies compared to men.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina

Soledad Gonzalez et al.

Summary: The study investigated the effectiveness of the first component of Gam-COVID-Vac in preventing infections, hospitalizations, and deaths in the elderly population, showing high effectiveness in reducing all three outcomes.

ECLINICALMEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection

Natalia Sherina et al.

Summary: The study shows that 85% of samples from COVID-19 patients had anti-SARS-CoV-2 antibodies within 4 weeks of symptom onset, while specific IgG antibodies and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. 80% of samples collected at 6-8 months after symptom onset still had anti-SARS-CoV-2 IgG antibodies, and specific memory B and T cell responses continued to develop and persist.

MED (2021)

Add to Collection

Article Immunology

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients

Frauke Muecksch et al.

Summary: Understanding the longitudinal trajectory of SARS-CoV-2 antibodies is crucial for diagnosis and immunity prediction. Different serological assays have varying suitability for surveillance and prediction of neutralization potency, with S-based assays better predicting neutralization levels over time.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Medicine, Research & Experimental

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

Giovanni Salvatori et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Microbiology

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

Amin Addetia et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

Add to Collection

Review Infectious Diseases

The role of regulatory T cells in immunopathogenesis and immunotherapy of viral infections

Ahmad Karkhah et al.

INFECTION GENETICS AND EVOLUTION (2018)

Add to Collection

Article Immunology

Regulatory T Cells Suppress Effector T Cell Proliferation by Limiting Division Destiny

Mark R. Dowling et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Review Immunology

Direct Antiviral Mechanisms of Interferon-Gamma

Soowon Kang et al.

IMMUNE NETWORK (2018)

Add to Collection

Review Immunology

Regulatory B Cells: Origin, Phenotype, and Function

Elizabeth C. Rosser et al.

IMMUNITY (2015)

Add to Collection

Article Immunology

CD8 T Cells Use IFN-γ To Protect against the Lethal Effects of a Respiratory Poxvirus Infection

John Goulding et al.

JOURNAL OF IMMUNOLOGY (2014)

Add to Collection

Article Virology

Persistence of Transgene Expression Influences CD8+ T-Cell Expansion and Maintenance following Immunization with Recombinant Adenovirus

Jonathan D. Finn et al.

JOURNAL OF VIROLOGY (2009)

Add to Collection

Article Virology

Role of regulatory T cells in coronavirus-induced acute encephalitis

Daniela Anghelina et al.

VIROLOGY (2009)

Add to Collection

Article Hematology

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells:: implications for their use as vaccines

Nia Tatsis et al.

BLOOD (2007)

Add to Collection

Article Multidisciplinary Sciences

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

UJ Buchholz et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

Add to Collection

Review Immunology

Central memory and effector memory T cell subsets: Function, generation, and maintenance

F Sallusto et al.

ANNUAL REVIEW OF IMMUNOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.